Vessel-Wave

Coming – July 15

Fixing The High Failure Rate of Aortic Stents

Date and Time

July 15

–

4:00 PM ET / 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

Aortic aneurysm treatment has a hidden long-term problem: today’s rigid vascular stent-grafts save lives in the short term, but they can contribute to hypertension, adverse cardiac remodeling, and long-term cardiovascular complications following otherwise successful procedures.

Vessel Wave Technologies is solving the problem with a disruptive technology platform. Vessel Wave is developing the first compliant aortic stent-graft designed to mimic the natural elasticity of the aorta, potentially reducing cardiovascular stress. Their proprietary biomaterial has already been validated in other implantable medical devices.

Their team includes founder Juan Parodi, MD performed the world’s first endovascular aortic repair, effectively creating the modern stent-graft category, supported by renowned biomaterials innovator Leonard Pinchuk, PhD and an experienced commercialization team. The company is already being backed by experts, including vascular surgeons, cardiac surgeons, and interventional radiologists who understand the value their compliant aortic implant can have on a large patient population with a critical unmet need.

Join our fireside chat with Vessel Wave CEO, Allen Conger, to for an in depth discussion of this growing problem and how their proven technology is poised to disrupt a multi-billion-dollar global market with more than 140,000 procedures performed each year.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.